Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Osteoporosis Drugs Tied to Lower Fracture Risk & Health Costs

Lisa Rapaport  |  August 13, 2018

(Reuters Health)—Older women with osteoporosis who consistently take a bisphosphonate may have a lower risk of fractures and lower total health costs than their counterparts who stop taking these drugs, a U.S. study suggests.

Researchers examined data on 294,369 women who were at least 66 years old, insured by Medicare and prescribed osteoporosis medicines for the first time at some point between 2009 and 2011.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Overall, roughly one third of these women consistently took their medications for at least a year with no gaps of two months or longer. The remaining two-thirds were considered “non-persistent” users because they had even longer lapses in medication use.

Among women who consistently took their drugs, annual fracture rates dropped from 16.2 fractures for every 100 patients in the six months before starting medication to 4.1 fractures for every 100 patients in the first 18 months of using osteoporosis drugs.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Women who were non-persistent users, however, had higher annual fracture rates: 19 fractures for every 100 patients in the six months before starting medication, and 7.3 fractures for every 100 patients over the first 18 months after drugs were prescribed.

“Osteoporosis medications can increase bone formation or decrease bone break down, resulting in increased bone density, therefore, decreased risk of fracture,” says lead study author Jiannong Liu, PhD, of the Hennepin Healthcare Research Institute in Minneapolis.

“When the medication stops, bone density will decrease again,” Dr. Liu says by email.

Widespread use of bisphosphonates in the U.S. coincided with a dramatic decline in fractures from the mid-1990s to the mid-2000s. But use of these medicines has declined in recent years following reports of rare, but serious side effects including unusual fractures of the thighbone, death of bone tissue in the jaw and esophageal cancer.

More than one-third of women prescribed bisphosphonates never fill their first prescription, researchers note in Osteoporosis International, online July 18.1

In the study, about nine in 10 women who didn’t consistently take their medicines stopped refilling their prescriptions.

Total average health costs for patients who didn’t take medicines as prescribed were $19,181 a year, compared with $14,476 for women who consistently took their drugs.

Fracture-related costs were higher without consistent medication use, averaging $641 a year compared with $292 for women who stuck with their medicines.

Without consistent drug use, women also had higher inpatient hospital costs: an average of $6,297 compared with $3,516 for those who did take the medicines.

The study wasn’t a controlled experiment designed to prove whether or how osteoporosis medication use directly reduces the risk of fractures or increases health costs.

Still, the results should reassure patients about the effectiveness of osteoporosis medicines when taken as directed, says Matthew Drake, MD, of the Mayo Clinic in Rochester, Minn.

“But they don’t work nearly as effectively when patients do not continue with them,” Dr. Drake, who wasn’t involved in the study, says by email.

For elderly patients in particular, fractures can lead to significant reductions in both independence and quality of life, Dr. Drake adds. Doctors and patients should consider this when weighing whether to start or stop osteoporosis drugs, he said.

“Some use is better than no use,” says Daniel Solomon, MD, MPH, a researcher at Brigham and Women’s Hospital and Harvard Medical School in Boston who wasn’t involved in the study.

“However, using the drugs as prescribed is always recommended,” Dr. Solomon says by email.


Reference

  1. Liu J, Guo H, Rai P, et al. Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis. Osteoporos Int. 2018 Jul 18. doi: 10.1007/s00198-018-4630-6. [Epub ahead of print]

Page: 1 2 | Multi-Page
Share: 

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesfracture riskFracturesOsteoporosisosteoporosis treatments

Related Articles

    Unexpected Benefits of Bisphosphonates after Hip Fracture

    February 3, 2012

    Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.

    Osteoporosis Experts Discuss Bisphosphonate Holidays

    November 24, 2020

    Dr. Hansen ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a…

    Build Up Bone

    June 1, 2007

    Current management of osteoporosis

    Prevent Osteoporotic Fractures with a Fracture Liaison Service

    May 18, 2019

    alice-photo / shutterstock.com Imagine leaving the hospital after suffering a heart attack without being treated for hypertension or being started on a beta blocker. What would we think of the hospital where patients are never educated about the relationship between treating hypertension and reducing myocardial infarction and stroke risk? Unfortunately, this happens every day with…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences